Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors

被引:30
作者
Tsuda, N
Kato, N
Murayama, C
Narazaki, M
Yokawa, T
机构
[1] Nihon Schering KK, Yodogawa Ku, Preclin Dev Dept, Osaka 5320004, Japan
[2] Nihon Schering KK, Yodogawa Ku, Drug Discovery Inst, Osaka 5320004, Japan
关键词
MRI; contrast agent; hepatocellular carcinoma; animal;
D O I
10.1097/01.rli.0000105331.11373.c0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives: To investigate whether dynamic and delayed magnetic resonance imaging (MRI) with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), a hepatobiliary MRI contrast agent, has potential for the differential diagnosis of experimental hepatic tumors. Methods: Twelve male rats received N-nitrosomorpholine solution as drinking water to induce hepatic tumors. After injection of Gd-EOB-DTPA, rats were subjected to dynamic and delayed MRI. The relative enhancement (RE) was calculated, and the time of the maximum RE (T-max) was evaluated. After MRI, liver was histologically analyzed. Results: One hundred sixty-three hepatic tumors 3-12 mm in diameter were induced after 18 weeks of treatment with 0.01 wt/vol% of N-nitrosomorpholine, and 81 of them were evaluated. The RE in hyperplastic nodules (HPNs) was significantly higher than that in moderately or poorly differentiated hepatocellular carcinomas (HCCs) in the late phase, whereas there was no significant difference in RE between well-differentiated HCCs and HPNs. The average T a in HPNs was about 13 minutes, whereas that of each differentiated HCCs was about 1 minute. Conclusions: It was possible to differentiate benign HPNs and malignant HCCs (especially well-differentiated HCCs) by evaluating the change of RE or comparison of T-max with Gd-EOB-DTPA-enhanced MRI.
引用
收藏
页码:80 / 88
页数:9
相关论文
共 29 条
[1]   Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: Results of an in vivo phase-I clinical evaluation [J].
Bollow, M ;
Taupitz, M ;
Hamm, B ;
Staks, T ;
Wolf, KJ ;
Weinmann, HJ .
EUROPEAN RADIOLOGY, 1997, 7 (01) :126-132
[2]   Intravenous contrast-enhanced Doppler sonography and intra-arterial carbon dioxide-enhanced sonography in the assessment of hepatocellular carcinoma vascularity before and after treatment [J].
Chen, RC ;
Chen, WT ;
Liao, LY ;
Cheng, NY ;
Wang, CK ;
Tu, HY ;
Wang, CS ;
Chen, PH .
ACTA RADIOLOGICA, 2002, 43 (04) :411-414
[3]   Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: Quantitative image analysis [J].
Fujita, M ;
Yamamoto, R ;
Takahashi, M ;
Tsuji, T ;
Yamanaka, T ;
Miyazawa, T ;
FritzZieroth, B ;
Terada, N ;
Kuroda, C .
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1997, 7 (04) :768-770
[4]  
Furuse J, 2001, J CLIN ULTRASOUND, V29, P1, DOI 10.1002/1097-0096(200101)29:1<1::AID-JCU1>3.0.CO
[5]  
2-F
[6]   Hepatic arterial phase MR imaging with automated bolus-detection three-dimensional fast gradient-recalled-echo sequence: Comparison with test-bolus method [J].
Hussain, HK ;
Londy, FJ ;
Francis, IR ;
Nghiem, HV ;
Weadock, WJ ;
Gebremariam, A ;
Chenevert, TL .
RADIOLOGY, 2003, 226 (02) :558-566
[7]   MAGNETIC-RESONANCE IMAGING-HISTOLOGIC CORRELATION OF SMALL HEPATOCELLULAR CARCINOMAS AND ADENOMATOUS HYPERPLASIAS [J].
INOUE, E ;
KURODA, C ;
NARUMI, Y ;
FUJITA, M ;
KADOTA, T ;
KURIYAMA, K ;
YOSHIOKA, H ;
ISHIGURO, S ;
SASAKI, Y ;
IMAOKA, S .
INVESTIGATIVE RADIOLOGY, 1993, 28 (08) :691-697
[8]  
Itai Y, 1989, Gan To Kagaku Ryoho, V16, P639
[9]  
Kaji I, 2001, INT J CANCER, V93, P441, DOI 10.1002/ijc.1353
[10]   Contrast media-enhanced power Doppler sonography for evaluation of hemangiomas and malignant tumors in the liver [J].
Karabacakoglu, A ;
Karakose, S ;
Cil, AS ;
Kaya, A .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 18 (01) :92-98